UCAR-T Cells

PreclinicalCell therapy

TThe Affiliated Hospital of Xuzhou Medical University

UCAR-T Cells is one of 38 biologic programs targeting Autoimmune Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune DiseaseActive, not recruiting

Autoimmune DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Autoimmune Disease

#DrugCompanyPhaseTrials

Myfortic

Novartis

Phase 3

1 2

Remicade

OOrganon and Co

Phase 3

2 3

Atgam

Novartis

Phase 2

2 4

Cytosar

Teva

Phase 2

1 5

Blincyto

Amgen

Phase 2

1 6

Soliris

Rayos

2 8

Alkeran

AApotex Inc.

Phase 2

1 9

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 2

1 10

Vepesid

AAvyxa

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Not yet recruiting

Autoimmune Disease

NCT07410377

N/AActive, not recruiting

Autoimmune Disease

NCT07155369

Clinical

Trials by Indication[1]

Autoimmune Disease2 trials

UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases

Not yet recruiting·TThe Affiliated Hospital of Xuzhou Medical University·Phase 1·NCT07410377·15 enrolled

UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases

Active, not recruiting·TThe Affiliated Hospital of Xuzhou Medical University·N/A·NCT07155369·18 enrolled

Anti-CD191 trial

Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL

Unknown status·—·Phase 1/2·NCT05639179·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for UCAR-T Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — UCAR-T Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for UCAR-T Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Affiliated Hospital of Xuzhou Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Preclinical[1]
Company: TThe Affiliated Hospital of Xuzhou Medical University

UCAR-T Cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Autoimmune Disease2 trials

Anti-CD191 trial

References

Drug Info

Quick Facts

Related News